Chong Kun Dang became the first to receive approval for its latecomer of the SGLT-2 inhibitor combination drug for diabetes, ‘Jardiance Duo (empagliflozin-metformin hydrochloride).

In addition, the company received the first generic exclusivity provided to companies that succeed challenging the original patent and be the first to apply for approval.

On the 12th, the Ministry of Food and Drug Safety approved three doses of the ‘Chong Kun Dang Empagliflozin Metformin Tablet.’

The product is a combination of metformin hydrochloride and empagliflozin L-proline. Unlike the existing Jardiance Duo, Chong Kun Dang’s product has added an amino acid, L-proline to its
Em